Stem cell therapy for joints typically costs $3,500 to $15,000 per site in the US, and you’ll almost always have to pay out of pocket. Clinics offer these injections for knee, back, hip, and shoulder problems, as well as arthritis more broadly. But the cost, recovery, and supporting evidence vary by joint. This guide breaks down those differences so you can better evaluate a quote before committing.
One important point applies across the board: the U.S. Food and Drug Administration has not approved any stem cell product for orthopedic conditions. That’s why insurance does not pay, and why you should approach claims about treating a specific joint with care.
How clinics market stem cells per joint
Clinics package the same basic procedure under different joint names. The injection, the cell source, and the imaging guidance rarely change much between a knee and a shoulder. The label changes to match your search.
That matters for two reasons. First, the marketing implies each joint has its own proven protocol. It does not. Second, per-joint pages let a clinic quote a per-joint price, which adds up fast when you have pain in more than one place.
Read a per-condition offer as a pricing frame, not a medical claim. The table below shows where each joint typically lands.
Cost by joint and condition
Most joint injections fall into a predictable band. Knees and backs carry the highest prices. Hips and shoulders usually cost less.
| Joint / condition | Typical US self-pay range | Relative evidence base |
|---|---|---|
| Knee | $4,000 – $12,000 | Most studied (Cochrane review exists) |
| Back / spine | $5,000 – $15,000 | Small, low-quality trials |
| Hip | $4,000 – $10,000 | Limited data |
| Shoulder | $3,500 – $9,000 | Very limited data |
| General arthritis (multiple joints) | $6,000 – $20,000+ | Varies by joint |
These ranges overlap because a “stem cell” label covers different products. Some clinics use your own bone marrow or fat, both natural sources of mesenchymal stem cells. Others use donated umbilical cord tissue. The source shifts both the price and how much evidence stands behind it. Our cost hub explains what drives each number.
What recovery usually involves
Recovery from a joint injection is typically short, but the timeline is not the same as proof it worked. Most clinics describe a same-day outpatient procedure, and you go home the same afternoon. Our guide to how the injection works walks through each step. How long the injection’s effects last is a separate question from how fast you recover, and our guide to how long it lasts breaks that down by joint.
Expect soreness at the injection site for a few days. Many protocols ask you to limit heavy activity for one to two weeks. Some clinics recommend physical therapy alongside the injection, which can make it hard to tell what actually helped.
A key caution: feeling better after weeks of rest and therapy is not evidence the cells did the work. Time, activity changes, and placebo effects all play a role. Our safety and side effects guide covers the risks separate from this normal recovery window.
The evidence caveat, stated plainly
The evidence for stem cell therapy in joints is limited and mostly low-certainty. This is the single most important thing to understand before you pay.
The strongest data is for the knee. A 2025 Cochrane review of stem cell injections for knee osteoarthritis pooled 25 studies. It found that, compared with placebo, stem cell injections may slightly improve pain and function, based on low-certainty evidence. The reviewers were uncertain about quality of life, safety, and whether the joint’s structure changed at all.
For back pain, hips, and shoulders the data is thinner still. No high-quality trial shows that these injections regrow cartilage or reverse arthritis. Short-term safety looks acceptable in studies, but serious harms have been reported at unregulated clinics.
Shared cautions for every joint
Not everyone is a good candidate for stem cell therapy, and the same red flags apply no matter which joint a clinic targets. Watch for these before you sign anything.
- “Cure” or “regrow” language. No joint injection is proven to regenerate cartilage. Treat these words as marketing.
- Insurance help offers. No FDA approval means no coverage. A clinic promising to “work with insurance” for a joint injection is a warning sign.
- Vague cell sourcing. Ask what cells are used, where they come from, and whether the product is FDA-cleared. A clear answer is a good sign.
- Pressure to treat multiple joints at once. Each added site adds thousands of dollars. Question whether every joint truly needs it.
- Candidacy varies by clinic. See who a clinic may rule out before you book a consult for any joint.
If the price is pushing you to consider treatment abroad, our guide to costs and oversight by country is worth reading first. Before you travel or pay a deposit, read how to vet a clinic. It walks through the checks that separate a careful provider from a sales operation.
Stem cells vs the alternatives per joint
For most joints, cheaper and better-studied options exist. Weigh them at the same time you weigh a stem cell quote.
| Option | Typical cost | Insurance? | Evidence |
|---|---|---|---|
| Physical therapy | $50 – $150 / visit | Often yes | Strong for most joints |
| Cortisone injection | $100 – $400 | Often yes | Good short-term relief |
| PRP injection | $500 – $2,500 | Rarely | Mixed, better than stem cells for some uses |
| Stem cell injection | $3,500 – $15,000 | No | Limited, low-certainty |
A cortisone shot usually costs less, is often covered by insurance, and gives good short-term relief, which makes it the more reasonable first step for most joint pain. Stem cell therapy may still be your choice once cortisone stops helping, but make that decision with the real number and the real evidence in front of you. Compare PRP directly in our PRP vs stem cell guide.
How to read a per-joint quote
Read every per-joint quote as a starting number, not the total. Clinics price per site and often suggest add-ons, so the headline figure rarely matches what you pay.
Take a common example. A quote of $6,000 for one knee becomes $12,000 with a suggested second injection, and $18,000 once a painful shoulder gets added. The per-joint frame is what makes multi-joint arthritis so costly.
Three questions cut through it. What is the total across every joint and repeat visit? What is bundled, and what is billed separately? If it does not help, refunds are rare and insurance will not reimburse an FDA-unapproved injection, so any money spent is very likely gone either way. A clinic that answers the first two questions plainly, and levels with you on the third, is worth more of your trust.
Conditions with No Established Stem Cell Option
This hub also gets searches for conditions with no dedicated page here. The reason is the same for all of them: no stem cell product has FDA approval for any of these conditions, and most of the research is still early-stage. The list below states where each one stands, so the search does not go unanswered.
- Hearing loss. No stem cell product has FDA approval for hearing loss, and clinics marketing injections for it are ahead of the evidence. Hearing aids and cochlear implants remain the options with real outcome data.
- Epilepsy. Research into stem cells for epilepsy stays at the small, early-stage level, with no FDA-approved product and no completed large trial. Anti-seizure medication, and surgery for some patients, remain the standard of care.
- Parkinson’s disease. No stem cell product has FDA approval for Parkinson’s disease. The furthest-along candidate is BlueRock Therapeutics’ bemdaneprocel, an embryonic-stem-cell-derived dopamine-neuron therapy that reported Phase I safety data in April 2026, a single early trial years from any approval decision. Medication and, for some patients, deep brain stimulation remain the options with an established track record.
- Kidney disease and chronic kidney disease (CKD). Patients researching CKD sometimes look for a stem cell alternative to dialysis, but none has FDA approval or a large controlled trial behind it. Dialysis and transplant carry decades of outcome data that no stem cell product for kidney disease has matched.
- Spinal stenosis. Spinal stenosis has drawn less stem cell research than the joint conditions above, and no product has FDA approval for it. Physical therapy, epidural injections, and surgery remain the options with real evidence behind them.
- Quadriplegia and spinal cord injury. Multiple research groups study stem cells for spinal cord injury, yet no product has FDA approval, and no trial has shown it restores lost function. Rehabilitation remains the one option with a track record for regaining any movement.
- Degenerative disc disease. Degenerative disc disease sits at roughly the same evidence stage as the joint conditions above. Small studies exist, no product has FDA approval, and none has shown it can regenerate a disc.
- Traumatic brain injury. No stem cell product has FDA approval for traumatic brain injury or any other form of brain damage. Research into neurological damage remains early-stage and limited to small trials, with no completed large controlled trial establishing benefit. Standard care relies on acute medical or surgical management followed by physical, occupational, and speech therapy, which have decades of outcome data behind them.
- Osteoporosis. No stem cell product has Food and Drug Administration (FDA) approval for osteoporosis, as noted in the regulator’s consumer alert. Clinical evidence for stem cell interventions remains early-stage and unproven. The established standard of care consists of FDA-approved bone-density medications, including bisphosphonates and related drug classes, as outlined by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
- ALS (amyotrophic lateral sclerosis). No stem cell product has FDA approval for amyotrophic lateral sclerosis (ALS), and clinical trials have not demonstrated clinical efficacy for stem cell therapy. Standard medical treatment relies on two FDA-approved drugs, riluzole and edaravone, documented by the National Institute of Neurological Disorders and Stroke (NINDS). Neither medication is a stem cell product.
- Dementia (Alzheimer’s disease). The FDA has approved no stem cell product for dementia or Alzheimer’s disease, leaving stem cell injections unsupported by authorized trial results. Standard treatment for early Alzheimer’s disease includes FDA-approved medications such as lecanemab and donanemab that target amyloid protein, as detailed by the National Institute on Aging (NIA). Neither medication involves stem cells.
- Ehlers-Danlos syndrome. Ehlers-Danlos syndrome is a group of inherited connective-tissue disorders, and no stem cell product has received FDA approval for its treatment. Regenerative claims for this condition lack clinical validation. As documented by the Genetic and Rare Diseases Information Center (GARD), standard management centers on physical therapy, joint bracing and protection, and pain management.
- Fragile X syndrome. Fragile X syndrome is caused by a mutation in the FMR1 gene, and no stem cell product has received FDA approval to treat it. The evidence base for stem cell interventions remains unproven and early-stage. Standard care consists of behavioral therapy and educational support, as detailed by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
If a clinic offers stem cell treatment for any condition above, the same checks apply as for a joint. Ask what the product is, whether it has FDA approval for that use, and how the cells are sourced and screened. Our how to vet a clinic guide covers the full checklist.
The bottom line
Stem cell therapy for joints is a self-pay, FDA-unapproved procedure with limited evidence behind it. Costs run $3,500 to $15,000 per site, the knee has the most data, and no joint has proof of cartilage repair. Pick your joint below for the full cost, recovery, and evidence breakdown, then price your safer alternatives before you decide.
Frequently asked questions
Is stem cell therapy FDA-approved for joints?
No. The FDA has not approved any stem cell product for osteoarthritis, tendon, disc, or other orthopedic conditions. Clinics offering joint injections operate outside FDA approval, so you pay out of pocket. See our FDA status guide.
How much does stem cell therapy cost per joint?
A single joint injection usually costs $3,500 to $12,000 in the US. Knees and backs sit at the higher end; shoulders and hips often cost less. Treating two sites roughly doubles the total.
Does the evidence show stem cells work for joints?
The evidence is limited and low-certainty. A 2025 Cochrane review found stem cell knee injections may slightly improve pain and function versus placebo, but the certainty is low. No study proves cartilage regrowth.
Which joint has the most research behind it?
The knee has by far the most trials. Back pain and hips have fewer, smaller studies. Shoulders have the least. More research does not mean proven benefit, only more data to judge.
Is stem cell therapy the same as PRP?
No. PRP uses concentrated platelets from your own blood and costs less. Many clinics blur the two or sell PRP as 'stem cells.' Compare them in our PRP vs stem cell guide.
Do I need stem cell therapy if physical therapy hasn't helped my joint?
Not automatically. Cortisone and PRP injections cost far less and, for many joints, carry similar or better evidence than stem cell therapy, so those are the more reasonable next step. Stem cell therapy is worth considering only after cheaper, better-studied options have failed, and even then the evidence for it stays limited and low-certainty.
Medical disclaimer. Medical Frontier is an independent educational resource. This page is for general information only and is not medical advice, diagnosis, or treatment, and does not create a doctor–patient relationship. Most regenerative therapies discussed here are not FDA-approved for the uses described and may be offered under limited exemptions or in clinical trials only. Always consult a licensed physician before making any treatment decision.